PT1930439E - Factores neurotróficos - Google Patents

Factores neurotróficos Download PDF

Info

Publication number
PT1930439E
PT1930439E PT07120461T PT07120461T PT1930439E PT 1930439 E PT1930439 E PT 1930439E PT 07120461 T PT07120461 T PT 07120461T PT 07120461 T PT07120461 T PT 07120461T PT 1930439 E PT1930439 E PT 1930439E
Authority
PT
Portugal
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
PT07120461T
Other languages
English (en)
Portuguese (pt)
Inventor
Dinah Wen Yee Sah
Anthony Rossomando
Teit E Johansen
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Publication of PT1930439E publication Critical patent/PT1930439E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PT07120461T 2001-03-12 2002-03-12 Factores neurotróficos PT1930439E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
PT1930439E true PT1930439E (pt) 2011-07-25

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
PT07120461T PT1930439E (pt) 2001-03-12 2002-03-12 Factores neurotróficos
PT02706759T PT1373503E (pt) 2001-03-12 2002-03-12 ''factores neurotróficos''

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02706759T PT1373503E (pt) 2001-03-12 2002-03-12 ''factores neurotróficos''

Country Status (15)

Country Link
US (1) US20020055467A1 (enExample)
EP (2) EP1930439B1 (enExample)
JP (2) JP3738008B2 (enExample)
CN (1) CN1268744C (enExample)
AT (2) ATE509103T1 (enExample)
AU (1) AU2002240943B2 (enExample)
CA (1) CA2440767C (enExample)
CY (1) CY1111750T1 (enExample)
DE (1) DE60223511T2 (enExample)
DK (2) DK1373503T3 (enExample)
ES (2) ES2366610T3 (enExample)
NZ (1) NZ528790A (enExample)
PT (2) PT1930439E (enExample)
SI (2) SI1373503T1 (enExample)
WO (1) WO2002072826A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
HUP0303900A3 (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) * 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
WO2003053476A1 (en) * 2001-12-19 2003-07-03 Lijun Wang Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
AU2004209966B9 (en) * 2003-01-31 2008-06-26 Biogen Ma Inc. Polymer conjugates of mutated neublastin
CA2522364C (en) * 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
ES2323066T3 (es) 2003-06-10 2009-07-06 Nsgene A/S Secrecion mejorada de neublastina.
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
ES2342397T3 (es) 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
PL1786454T3 (pl) * 2004-08-19 2010-12-31 Biogen Ma Inc Odmiany neublastyny
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009045813A1 (en) * 2007-10-01 2009-04-09 Vgx Pharmaceuticals, Inc. Materials and methods for the delivery of biomolecules to cells of an organ
CN108079279B (zh) * 2010-10-01 2022-04-12 霍巴治疗公司 镍纹蛋白用于治疗异常性疼痛、痛觉过敏、自发性疼痛和幻痛的用途
WO2019221528A1 (en) * 2018-05-17 2019-11-21 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
CA3220333A1 (en) 2021-05-18 2022-11-24 Musashino University Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
BR9710665A (pt) 1996-05-08 1999-08-17 Biogen Inc Compostos que promovem o desenvolvimento do tecido
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
ES2287020T3 (es) * 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.

Also Published As

Publication number Publication date
CA2440767C (en) 2012-05-29
JP2005198656A (ja) 2005-07-28
US20020055467A1 (en) 2002-05-09
CN1268744C (zh) 2006-08-09
DE60223511D1 (de) 2007-12-27
AU2002240943A2 (en) 2002-09-24
EP1373503A2 (en) 2004-01-02
AU2002240943B2 (en) 2007-05-10
PT1373503E (pt) 2008-02-26
ES2366610T3 (es) 2011-10-21
EP1930439A1 (en) 2008-06-11
ATE378353T1 (de) 2007-11-15
DK1930439T3 (da) 2011-08-29
ATE509103T1 (de) 2011-05-15
HK1120556A1 (en) 2009-04-03
DE60223511T2 (de) 2008-10-23
JP2004531242A (ja) 2004-10-14
CY1111750T1 (el) 2015-10-07
DK1373503T3 (da) 2008-03-25
SI1930439T1 (sl) 2011-09-30
ES2296899T3 (es) 2008-05-01
WO2002072826A3 (en) 2003-04-10
CN1509333A (zh) 2004-06-30
SI1373503T1 (sl) 2008-04-30
EP1930439B1 (en) 2011-05-11
JP3738008B2 (ja) 2006-01-25
WO2002072826A2 (en) 2002-09-19
EP1373503B1 (en) 2007-11-14
NZ528790A (en) 2004-06-25
CA2440767A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
SI1095140T1 (sl) Nevrotrofični dejavniki
IL161016A (en) Polypeptides capable of ang-2 binding
PT1015585E (pt) Homologos de ligandos de tie
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2003080795A8 (en) Novel nucleic acids and secreted polypeptides
WO2007045019A3 (en) Polyoleosins
WO2003025142A3 (en) Novel nucleic acids and secreted polypeptides
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
EA200100110A1 (ru) Нейротрофические факторы
WO2001021794A3 (en) Smad associating polypeptides
WO2001057187A3 (en) Novel bone marrow nucleic acids and polypeptides
WO2001088091A3 (en) Novel bone marrow nucleic acids and polypeptides
EP1375656A4 (en) NEW PROTEINS AND DNA ENCODING IT
TW200519206A (en) Methods for producing novel medaka and novel medaka
WO2004039319A3 (en) Novel human polypeptides encoded by polynucleotides